GINKGO BIOWORKS HOLDINGS INC (DNA) Stock Price, Forecast & Analysis
NYSE:DNA • US37611X2099
DNA Key Statistics, Chart & Performance
The current stock price of DNA is 8.86 USD. In the past month the price decreased by -10.05%. In the past year, price increased by 7.52%.
DNA Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to DNA. When comparing the yearly performance of all stocks, DNA turns out to be only a medium performer in the overall market: it outperformed 44.39% of all stocks.
DNA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to DNA. DNA has a great financial health rating, but its profitability evaluates not so good.
DNA Financial Highlights
Over the last trailing twelve months DNA reported a non-GAAP Earnings per Share(EPS) of -6.23. The EPS increased by 45.06% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -28.55% | ||
| ROE | -60.66% | ||
| Debt/Equity | 0 |
DNA Forecast & Estimates
11 analysts have analysed DNA and the average price target is 10.2 USD. This implies a price increase of 15.12% is expected in the next year compared to the current price of 8.86.
For the next year, analysts expect an EPS growth of 36.28% and a revenue growth -23.62% for DNA
DNA Ownership
DNA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 20.77 | 194.032B | ||
| DHR | DANAHER CORP | 24.63 | 149.099B | ||
| BRKRP | BRUKER CORP - BRKR 6 3/8 09/01/28 | 142.41 | 47.173B | ||
| A | AGILENT TECHNOLOGIES INC | 20.55 | 35.129B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 29.84 | 28.325B | ||
| IQV | IQVIA HOLDINGS INC | 12.6 | 27.528B | ||
| WAT | WATERS CORP | 22.55 | 19.513B | ||
| ILMN | ILLUMINA INC | 23.74 | 18.418B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 31.26 | 17.569B | ||
| MEDP | MEDPACE HOLDINGS INC | 26.31 | 12.535B |
Related stock screener links
View all stocks in the Life Sciences Tools & Services Industry | View all stocks in the Health Care Sector | View all stocks on the New York Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About DNA
Company Profile
Ginkgo Bioworks Holdings, Inc. is a biotech company. The company is headquartered in Boston, Massachusetts and currently employs 834 full-time employees. The company went IPO on 2021-04-19. Its segments include Cell Engineering and Biosecurity. The Cell Engineering consists of research and development services performed under collaboration and license agreements relating to its cell programming platform. Its cell programming platform includes two core assets: the Foundry, and Codebase. The Biosecurity segment consists of biomonitoring and bioinformatics support services, offered to both government and non-government customers through its two core offerings: Canopy and Horizon. The firm provides comprehensive research and development services spanning the genetic medicine modalities: gene therapy, cell therapy and gene editing, and RNA therapeutics.
Company Info
GINKGO BIOWORKS HOLDINGS INC
27 Drydock Avenue, 8th Floor
Boston MASSACHUSETTS US
CEO: Harry E. Sloan
Employees: 834
Phone: 18774425362
GINKGO BIOWORKS HOLDINGS INC / DNA FAQ
What does GINKGO BIOWORKS HOLDINGS INC do?
Ginkgo Bioworks Holdings, Inc. is a biotech company. The company is headquartered in Boston, Massachusetts and currently employs 834 full-time employees. The company went IPO on 2021-04-19. Its segments include Cell Engineering and Biosecurity. The Cell Engineering consists of research and development services performed under collaboration and license agreements relating to its cell programming platform. Its cell programming platform includes two core assets: the Foundry, and Codebase. The Biosecurity segment consists of biomonitoring and bioinformatics support services, offered to both government and non-government customers through its two core offerings: Canopy and Horizon. The firm provides comprehensive research and development services spanning the genetic medicine modalities: gene therapy, cell therapy and gene editing, and RNA therapeutics.
What is the current price of DNA stock?
The current stock price of DNA is 8.86 USD.
Does GINKGO BIOWORKS HOLDINGS INC pay dividends?
DNA does not pay a dividend.
What is the ChartMill technical and fundamental rating of DNA stock?
DNA has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Should I buy DNA stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on DNA.
What is GINKGO BIOWORKS HOLDINGS INC worth?
GINKGO BIOWORKS HOLDINGS INC (DNA) has a market capitalization of 510.25M USD. This makes DNA a Small Cap stock.
Who owns GINKGO BIOWORKS HOLDINGS INC?
You can find the ownership structure of GINKGO BIOWORKS HOLDINGS INC (DNA) on the Ownership tab.